|Bid||104.00 x 1400|
|Ask||105.77 x 900|
|Day's range||103.71 - 105.25|
|52-week range||91.51 - 122.16|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||34.44|
|Forward dividend & yield||1.57 (1.36%)|
|Ex-dividend date||25 Mar 2022|
|1y target est||128.50|
Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.
Bagsværd, Denmark, 15 August 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in
Three Motley Fool contributors have identified stocks to buy and hold forever. Here's why they chose Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Eli Lilly): If you're planning to hold a stock forever, then you need to be comfortable with its growth potential.